S&P 500   3,753.18 (-0.80%)
DOW   29,974.93 (-0.99%)
QQQ   280.24 (-0.62%)
AAPL   145.54 (-0.59%)
MSFT   247.33 (-0.75%)
META   139.48 (+0.36%)
GOOGL   101.56 (+0.13%)
AMZN   120.58 (-0.31%)
TSLA   239.65 (-0.48%)
NVDA   131.72 (-0.28%)
NIO   14.94 (-6.86%)
BABA   84.58 (+0.23%)
AMD   68.16 (+0.32%)
T   15.39 (-3.39%)
MU   54.75 (+0.04%)
CGC   3.53 (+14.98%)
F   12.37 (-1.12%)
GE   66.13 (-1.94%)
DIS   100.14 (-0.65%)
AMC   7.24 (-1.23%)
PYPL   94.44 (+0.65%)
PFE   43.15 (-2.20%)
NFLX   240.72 (+1.69%)
S&P 500   3,753.18 (-0.80%)
DOW   29,974.93 (-0.99%)
QQQ   280.24 (-0.62%)
AAPL   145.54 (-0.59%)
MSFT   247.33 (-0.75%)
META   139.48 (+0.36%)
GOOGL   101.56 (+0.13%)
AMZN   120.58 (-0.31%)
TSLA   239.65 (-0.48%)
NVDA   131.72 (-0.28%)
NIO   14.94 (-6.86%)
BABA   84.58 (+0.23%)
AMD   68.16 (+0.32%)
T   15.39 (-3.39%)
MU   54.75 (+0.04%)
CGC   3.53 (+14.98%)
F   12.37 (-1.12%)
GE   66.13 (-1.94%)
DIS   100.14 (-0.65%)
AMC   7.24 (-1.23%)
PYPL   94.44 (+0.65%)
PFE   43.15 (-2.20%)
NFLX   240.72 (+1.69%)
S&P 500   3,753.18 (-0.80%)
DOW   29,974.93 (-0.99%)
QQQ   280.24 (-0.62%)
AAPL   145.54 (-0.59%)
MSFT   247.33 (-0.75%)
META   139.48 (+0.36%)
GOOGL   101.56 (+0.13%)
AMZN   120.58 (-0.31%)
TSLA   239.65 (-0.48%)
NVDA   131.72 (-0.28%)
NIO   14.94 (-6.86%)
BABA   84.58 (+0.23%)
AMD   68.16 (+0.32%)
T   15.39 (-3.39%)
MU   54.75 (+0.04%)
CGC   3.53 (+14.98%)
F   12.37 (-1.12%)
GE   66.13 (-1.94%)
DIS   100.14 (-0.65%)
AMC   7.24 (-1.23%)
PYPL   94.44 (+0.65%)
PFE   43.15 (-2.20%)
NFLX   240.72 (+1.69%)
S&P 500   3,753.18 (-0.80%)
DOW   29,974.93 (-0.99%)
QQQ   280.24 (-0.62%)
AAPL   145.54 (-0.59%)
MSFT   247.33 (-0.75%)
META   139.48 (+0.36%)
GOOGL   101.56 (+0.13%)
AMZN   120.58 (-0.31%)
TSLA   239.65 (-0.48%)
NVDA   131.72 (-0.28%)
NIO   14.94 (-6.86%)
BABA   84.58 (+0.23%)
AMD   68.16 (+0.32%)
T   15.39 (-3.39%)
MU   54.75 (+0.04%)
CGC   3.53 (+14.98%)
F   12.37 (-1.12%)
GE   66.13 (-1.94%)
DIS   100.14 (-0.65%)
AMC   7.24 (-1.23%)
PYPL   94.44 (+0.65%)
PFE   43.15 (-2.20%)
NFLX   240.72 (+1.69%)
NASDAQ:PTGX

Protagonist Therapeutics - PTGX Stock Forecast, Price & News

$8.69
+0.07 (+0.81%)
(As of 10/6/2022 03:22 PM ET)
Add
Compare
Today's Range
$8.56
$8.87
50-Day Range
$8.02
$11.71
52-Week Range
$6.91
$38.11
Volume
11,733 shs
Average Volume
1.03 million shs
Market Capitalization
$426.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$43.71

Protagonist Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
406.5% Upside
$43.71 Price Target
Short Interest
Bearish
6.46% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.54mentions of Protagonist Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.08) to ($3.63) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.73 out of 5 stars

Medical Sector

879th out of 1,072 stocks

Pharmaceutical Preparations Industry

437th out of 534 stocks

PTGX stock logo

About Protagonist Therapeutics (NASDAQ:PTGX) Stock

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Receive PTGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PTGX Stock News Headlines

PTGX Protagonist Therapeutics, Inc.
PTGX, MNKD and AVGO are among after hour movers
Why this East Bay biotech lost nearly 22% of its value
See More Headlines
Receive PTGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PTGX Company Calendar

Last Earnings
8/04/2022
Today
10/06/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PTGX
Fax
N/A
Employees
118
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$43.71
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$21.00
Forecasted Upside/Downside
+403.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-125,550,000.00
Net Margins
-291.70%
Pretax Margin
-291.70%

Debt

Sales & Book Value

Annual Sales
$27.36 million
Book Value
$6.29 per share

Miscellaneous

Free Float
46,483,000
Market Cap
$426.51 million
Optionable
Not Optionable
Beta
2.43

Key Executives

  • Dr. Dinesh V. Patel Ph.D. (Age 65)
    CEO, Pres, Sec. & Director
    Comp: $1.04M
  • Dr. David Y. Liu Ph.D. (Age 72)
    Chief R&D Strategy Officer
    Comp: $702.87k
  • Dr. Suneel K. Gupta Ph.D. (Age 63)
    Chief Devel. Officer
    Comp: $698.72k
  • Dr. Richard S. Shames (Age 62)
    Clinical Advisor
  • Mr. Asif Ali
    Exec. VP & Chief Financial Officer
  • Mr. Mohammad Masjedizadeh
    Exec. VP & CTO
  • Mr. Matthew M. Gosling (Age 51)
    Exec. VP & Gen. Counsel
  • Ms. Carena Spivey
    Exec. Director of HR
  • Dr. Ashok Bhandari Ph.D. (Age 58)
    Sr. VP of Discovery Chemistry & Process Research
  • Dr. Scott Eric Plevy M.D.
    Exec. VP and Therapeutic Head of Gastroenterology













PTGX Stock - Frequently Asked Questions

Should I buy or sell Protagonist Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PTGX shares.
View PTGX analyst ratings
or view top-rated stocks.

What is Protagonist Therapeutics' stock price forecast for 2022?

7 analysts have issued 12 month price objectives for Protagonist Therapeutics' shares. Their PTGX share price forecasts range from $21.00 to $60.00. On average, they anticipate the company's share price to reach $43.71 in the next year. This suggests a possible upside of 407.1% from the stock's current price.
View analysts price targets for PTGX
or view top-rated stocks among Wall Street analysts.

How have PTGX shares performed in 2022?

Protagonist Therapeutics' stock was trading at $34.20 at the beginning of the year. Since then, PTGX stock has decreased by 74.8% and is now trading at $8.62.
View the best growth stocks for 2022 here
.

When is Protagonist Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our PTGX earnings forecast
.

How were Protagonist Therapeutics' earnings last quarter?

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) issued its quarterly earnings data on Thursday, August, 4th. The company reported ($0.84) earnings per share for the quarter, topping analysts' consensus estimates of ($0.99) by $0.15. The company earned $0.86 million during the quarter, compared to the consensus estimate of $2.30 million. Protagonist Therapeutics had a negative net margin of 291.70% and a negative trailing twelve-month return on equity of 44.25%.

What other stocks do shareholders of Protagonist Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), ImmunoGen (IMGN), SCYNEXIS (SCYX), Energy Transfer (ET), Strongbridge Biopharma (SBBP), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX) and Sorrento Therapeutics (SRNE).

When did Protagonist Therapeutics IPO?

(PTGX) raised $70 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 5,800,000 shares at $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO.

What is Protagonist Therapeutics' stock symbol?

Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX."

How do I buy shares of Protagonist Therapeutics?

Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Protagonist Therapeutics' stock price today?

One share of PTGX stock can currently be purchased for approximately $8.62.

How much money does Protagonist Therapeutics make?

Protagonist Therapeutics (NASDAQ:PTGX) has a market capitalization of $423.07 million and generates $27.36 million in revenue each year. The company earns $-125,550,000.00 in net income (profit) each year or ($2.74) on an earnings per share basis.

How many employees does Protagonist Therapeutics have?

The company employs 118 workers across the globe.

How can I contact Protagonist Therapeutics?

Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The official website for the company is www.protagonist-inc.com. The company can be reached via phone at (510) 474-0170 or via email at bkorb@soleburytrout.com.

This page (NASDAQ:PTGX) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.